Group 1: Market Overview - The equity market continues to rise, with equity funds showing a net value increase of 3.06%, particularly in the healthcare theme funds which have demonstrated significant performance advantages [2] - Passive funds are seeing a shift, with inflows into financial real estate and dividend-themed ETFs, while large-cap broad-based ETFs are experiencing outflows [2] Group 2: Industry Research - The Yarlung Tsangpo River downstream hydropower project has officially commenced, with a total investment of approximately 1.2 trillion yuan and an installed capacity of 60-81 million kilowatts, benefiting the "duopoly" in hydropower equipment [4] - The project is expected to generate substantial construction and material orders, significantly boosting infrastructure investment growth in China [5] Group 3: Real Estate Market - As of July 20, 2025, new home transactions in 20 cities totaled 441,000 units, a decrease of 3.5%, while second-hand home transactions increased by 12.8% [6] Group 4: Steel Industry - The expectation for the exit of outdated production capacity has risen, with rebar prices reaching a new high since April 2025, indicating potential recovery in steel sector profitability [8] Group 5: Pharmaceutical Industry - The recent updates on the 2024 medical insurance fund and centralized procurement policies indicate a strong growth momentum for the innovative drug sector, with several companies successfully launching innovative drugs internationally [9] Group 6: Chemical Industry - The Ministry of Industry and Information Technology is set to introduce a stable growth plan for the petrochemical industry, which is expected to optimize the industry structure by phasing out outdated production capacity [10] Group 7: Machinery Industry - The engineering machinery sector is anticipated to benefit from the commencement of the Yarlung hydropower project, with domestic sales recovering and export volumes maintaining growth [10] Group 8: Company Research - The report on Mai Fushi indicates a strong market position due to its comprehensive product matrix and high customer retention, with projected revenues of 2.36 billion, 3.17 billion, and 4.13 billion yuan for 2025-2027 [11]

Core Insights - Kangfang Biopharma is a global leader in bispecific antibodies, with its core product, AK112 (PD-1/VEGF bispecific antibody), becoming the first bispecific antibody to surpass Keytruda in mPFS for first-line lung cancer treatment [1] - The report updates on AK112's clinical data both domestically and internationally, highlighting its potential as a blockbuster drug, and discusses the differentiation between AK104 and AK112 [1][2] - Future focus areas include the 2025 ESMO HARMONi-6 clinical data release, overseas clinical progress for AK112 and AK104, domestic healthcare negotiations in 2025, and potential business development opportunities [1] Commercialization Capability - Both Kadunili and AK112 have been included in healthcare insurance, with Kadunili achieving sales of 546 million yuan in its first year and 1.358 billion yuan in 2023, representing a growth of 148.5% [2] - AK112 generated approximately 350 million yuan in its first year post-launch, with the negotiated price dropping to 736 yuan per bottle, a reduction of 68% [2] - The overseas development of AK112 is supported by a $5 billion licensing agreement with Summit Therapeutics, which is conducting three ongoing Phase III clinical trials [2] R&D Pipeline - The company has over 50 innovative drug candidates targeting major diseases, with 24 new drugs in clinical research and commercialization stages, including 15 potential first-in-class or best-in-class bispecific antibodies [2] - 17 Phase III clinical trials are currently underway, including PD-1/LAG-3 bispecific antibody AK129 and TIGIT/TGF-β fusion protein AK130 [2] - The exploration of new therapeutic approaches through bispecific antibodies and ADCs is expected to become a second growth point for the company [2] Company Catalysts - Upcoming catalysts include the Phase III HARMONi-6 study data readout for AK112 at the ESMO conference in October, and potential updates on HARMONi-3 and HARMONi-7 overseas enrollment [3] - For AK104, data readout for post-operative adjuvant therapy in liver cancer is anticipated, along with potential global development plans [3][4] - Other significant data readouts include the final data for the combination of Paimu Li and Anru Te Ni in advanced liver cancer and the monoclonal antibody for moderate to severe atopic dermatitis [4] Financial Projections - The company is projected to achieve revenues of 3.732 billion yuan, 5.149 billion yuan, and 7.628 billion yuan in 2025, 2026, and 2027, respectively, with growth rates of 75.70%, 37.98%, and 48.14% [4] - Expected net profits for the same years are -75 million yuan, 335 million yuan, and 1.401 billion yuan [4] - The ongoing expansion of the R&D pipeline and the successful launch of innovative products are expected to contribute positively to the company's long-term sustainable growth [4]

Group 1 - The core index, the CESHKB, experienced a decline of 1.62%, closing at 8758.46 points with a trading volume of 12.171 billion [1] - Over the past month, the CESHKB has increased by 21.79%, by 64.09% over the last three months, and has risen 98.69% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (13.31%), Innovent Biologics (9.84%), 3SBio (9.12%), BeiGene (8.94%), WuXi Biologics (8.9%), WuXi AppTec (5.65%), Kintor Pharmaceutical (4.91%), Zai Lab (4.82%), Nuo Therapeutics (4.34%), and Kingstar Biotech (4.0%) [1] - The CESHKB is fully composed of stocks listed on the Hong Kong Stock Exchange, with a sector breakdown showing 59.75% in biopharmaceuticals, 23.83% in pharmaceutical and biotechnology services, 14.25% in chemical drugs, and 2.17% in medical devices [2]

Group 1 - The article provides an overview of the performance of various funds, highlighting the top and bottom performers based on net asset value updates as of July 21, 2025 [3][4]. - The top 10 funds with the highest net value growth include several ETFs focused on construction materials, indicating a strong performance in this sector [3]. - The bottom 10 funds, such as the Morgan Stanley Hong Kong-Shanghai Select Mixed Fund C, show a decline in net value, suggesting challenges in their respective strategies [4]. Group 2 - The Shanghai Composite Index experienced a rebound, with a trading volume of 1.72 trillion, and a significant number of stocks advancing compared to those declining [6]. - The construction materials and engineering machinery sectors led the market with gains exceeding 4%, reflecting positive sentiment in these industries [6]. - The fund with the fastest net value growth is the Fortune China Securities All Index Construction Materials ETF, which aligns with the strong performance of the construction materials sector [6]. Group 3 - The top holdings of the leading construction materials fund include companies like Conch Cement and North New Materials, which have shown significant price increases [7]. - The fund's style is categorized as passive index tracking, specifically following the China Securities All Index Construction Materials Index, indicating a focus on the construction materials industry [7]. - In contrast, the pharmaceutical sector funds, such as the Morgan Stanley Hong Kong-Shanghai Select Mixed Fund, have underperformed, with significant declines in key holdings like BeiGene and Zai Lab [7].

Group 1 - The core index of the CSI Hong Kong Stock Connect Innovative Drug Index (931250) experienced a decline of 1.42%, closing at 1114.48 points with a trading volume of 16.63 billion yuan [1] - Over the past month, the index has increased by 22.12%, by 65.37% over the last three months, and has risen 94.38% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Group 2 - The top ten weighted companies in the index include: CanSino Biologics (10.0%), Innovent Biologics (9.88%), BeiGene (8.97%), WuXi Biologics (8.93%), China Biologic Products (7.69%), CSPC Pharmaceutical Group (7.19%), 3SBio (5.66%), Hansoh Pharmaceutical (4.23%), WuXi AppTec (3.5%), and Kelun-Biotech (3.05%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - In terms of industry composition, the index's sample holdings consist of 40.89% in drug formulations, 40.00% in other biopharmaceuticals, 18.70% in pharmaceutical and biotechnology services, and 0.41% in vaccines [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Special circumstances may lead to temporary adjustments to the index, such as delisting of samples or corporate actions like mergers and acquisitions [2]

Core Insights - The China-Hong Kong-US Listed Chinese and American Technology Index has shown significant growth, with a 9.54% increase over the past month, 29.90% over the past three months, and 25.59% year-to-date [1] Group 1: Index Performance - The index is designed to reflect the overall performance of high liquidity and high market capitalization technology companies listed in Hong Kong and the US, using an equal-weighted calculation method [1] - The index was established on December 31, 2010, with a base point of 1000.0 [1] Group 2: Top Holdings - The top ten holdings of the index include: - Kangfang Biotech (2.97%) - Oracle Corp (2.55%) - Bilibili (2.38%) - Advanced Micro Devices Inc. (2.37%) - NIO (2.24%) - NVIDIA Corp (2.22%) - Innovent Biologics (2.20%) - Sunny Optical Technology (2.15%) - Palantir Technologies Inc (2.14%) - Avago Technologies Ltd (2.13%) [1] Group 3: Market Composition - The index's market composition shows that the Nasdaq Global Select Market accounts for 47.02%, the Hong Kong Stock Exchange for 31.03%, the New York Stock Exchange for 19.58%, and the Nasdaq Capital Market for 2.37% [2] - In terms of industry composition, Information Technology represents 44.27%, Consumer Discretionary 17.44%, Communication Services 14.09%, and Healthcare 11.16% [2] Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical and biotechnology sector has shown a weekly return of 4.00%, outperforming the CSI 300 by 2.91%, ranking second among 31 primary sub-industry indices [3][8] - The report emphasizes the importance of innovation and recovery as key investment themes, highlighting the ongoing enthusiasm for innovative drugs driven by policy incentives and clinical data [10] - Notable mergers and acquisitions, such as China Biopharmaceutical's acquisition of Lixin Pharmaceutical for approximately $1 billion, are seen as significant milestones in the industry [9][10] Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's monthly return was 9.44%, ranking fourth among 31 primary sub-industry indices, with the medical services sub-sector leading with a 15.72% increase [8][22] - The chemical pharmaceuticals sub-sector had the highest weekly return of 6.86% [32] 2. Market Performance and Valuation - The current PE (TTM) for the pharmaceutical and biotechnology industry is 30.03, which is below the historical average of 30.89 [14][17] - The industry has shown a 21.25% increase over the last six months, outperforming the CSI 300 by 14.79% [12][14] 3. Stock Performance - Top-performing stocks in the past week include Borui Pharmaceutical, Lisheng Pharmaceutical, and Nanxin Pharmaceutical, with increases of 42.35%, 41.68%, and 34.95% respectively [37] - In the Hong Kong market, stocks like Sanofi Biologics and Lepu Medical have also shown significant gains of 63.79% and 62.04% [41] 4. Industry and Company Dynamics - Recent policy developments include the Shanghai Municipal Drug Administration's action plan for regulating online drug sales from 2025 to 2027 [44] - The National Healthcare Security Administration has initiated the eleventh batch of centralized drug procurement, which will include 55 varieties [44]

Group 1 - The core trend observed in the second quarter of 2025 is that many prominent fund managers are increasing their positions in the innovative drug sector, indicating a growing interest in this area [1] - Yongying Fund's Gao Nan reported that the total scale of the funds he manages reached 15.326 billion yuan, a significant increase of nearly 3.5 billion yuan compared to the end of the first quarter [2] - Several funds managed by Gao Nan achieved net value growth exceeding 10%, ranking among the top in their category, showcasing a dual increase in performance and scale [2] Group 2 - The top ten holdings of Gao Nan's flagship fund, Yongying Ruixin, saw significant adjustments, with new additions from the communication equipment sector and innovative drug companies [3] - Major new holdings include companies like ZTE and Innovent Biologics, while positions in BYD and Ninebot were exited [3][4] - The three main investment directions for Gao Nan's funds are communication (TMT), innovative drugs, and light manufacturing, reflecting a clear structural adjustment in response to market themes [4] Group 3 - Gao Nan emphasizes stock selection based on company growth potential and earnings realization, aiming to reduce industry concentration while capturing growth opportunities [5] - The Yongying Technology Driven Fund plans to increase exposure to the artificial intelligence supply chain and reallocate in defense and biomedicine sectors [5] - Gao Nan expresses cautious optimism for the second half of the year, noting improved liquidity conditions and a strong financial risk prevention system established by the government [5] Group 4 - Ruiyuan Fund's Fu Pengbo also significantly increased allocations to the pharmaceutical sector, particularly in innovative drugs, during the second quarter [6] - The Ruiyuan Growth Value Mixed Fund reached a scale of 18.666 billion yuan, with a net value growth rate of 5.80%, outperforming its benchmark by 4.13 percentage points [6][7] - Fu Pengbo's portfolio is heavily weighted towards electronics, internet technology, precision manufacturing, and pharmaceuticals, with a stock position exceeding 92% [7] Group 5 - Fu Pengbo's strategy involves increasing holdings in the pharmaceutical sector, covering innovative drugs and traditional medicine benefiting from AI, while reducing exposure to traditional energy companies [10] - He plans to closely monitor mid-year reports from listed companies and seek industries and companies with rising prosperity [11] - Both Gao Nan and Fu Pengbo share a focus on innovative drugs, providing investors with a reference point for market trends and industry movements [11]

2025 年 7 月 21 日 行业研究 ——医药生物行业跨市场周报（20250720） 要点 行情回顾：上周， A 股医药生物指数上涨 4.00%，跑赢沪深 300 指数 2.91pp， 跑赢创业板综指 1.75pp，在 31 个子行业中排名第 2。港股恒生医疗健康指数上 涨 12.0%，跑赢恒生国企指数 8.56pp。 上市公司研发进度跟踪：上周，百奥泰的BAT5906注射液、恒瑞医药的 HRS-2162 注射液的临床申请新进承办。华东医药的 HDM1002、正大天晴的 bosakitug 正 在进行三期临床；联邦制药的 UBT251 正在进行二期临床；海思科的 HSK45030 正在进行一期临床。 本周观点：医保与集采支撑有力，创新药行业成长动能强劲 近日，国家公布了 2024 年医保基金的运行状况与集采政策最新动态。截至 2024 年底，全国基本医疗保险（含生育保险）基金总收入 34913.37 亿元，总支出 29764.03 亿元，全国基本医保统筹基金累计结存 38628.5 亿元。整体来看，医 保基金收支结构合理，体现出运行的稳健性。7 月 15 日，国家组织药品联合采 购办公室公布第十一批集采品 ...

Core Insights - The article highlights that only 13 women globally have become billionaires by founding healthcare companies, with 7 of them from China, indicating a significant presence of Chinese female entrepreneurs in the healthcare sector [1][3]. Industry Overview - The Chinese biopharmaceutical industry is experiencing a transformative phase, referred to as the "DeepSeek moment," as it evolves from being a "generic drug powerhouse" to a competitive force against Western innovation in pharmaceuticals [2]. - In 2024, over 1,250 new drug candidates are expected to enter the research and development phase in China, surpassing the European Union and nearly matching the United States' 1,440 candidates [2]. - Nearly one-third of the drug candidates licensed by large pharmaceutical companies in 2024 are from Chinese firms, a significant increase from zero in 2019 [3]. Company Highlights - **Hansoh Pharmaceutical Group**: Founded by Zhong Huijuan, the company reported a total revenue of approximately 12.26 billion yuan in 2024, with a year-on-year growth of about 21.3% [7]. - **Aimeike**: Founded by Jian Jun, the company specializes in hyaluronic acid production and was listed on the A-share market in 2020, achieving a market value exceeding 170 billion yuan [10]. - **Qizheng Tibetan Medicine**: Founded by Lei Jufang, the company generated sales revenue of 1.655 billion yuan in 2024, with a year-on-year growth of 16.31% [14]. - **Haisco Pharmaceutical Group**: Co-founded by Fan Xiulian, the company reported a revenue of 3.721 billion yuan in 2024, with a year-on-year increase of 10.92% [17]. - **Teva Biopharmaceuticals**: Founded by Yang Ying, the company has shown rapid growth, with revenues increasing from 1.527 billion yuan in 2022 to 2.817 billion yuan in 2024 [18]. - **Kangfang Biopharmaceutical**: Founded by Xia Yu, the company has developed several innovative drugs and is recognized for its leading position in the biopharmaceutical sector [23]. - **Xinlitai**: Co-founded by Liao Qingqing, the company has shifted focus to self-research and development, achieving a revenue of 4.012 billion yuan in 2024, with a year-on-year growth of 19.22% [26].